Related by context. All words. (Click for frequent words.) 76 androgen deprivation 74 androgen ablation 73 preoperative chemotherapy 72 postoperative chemotherapy 71 adjuvant radiotherapy 70 APTIVUS r 70 EBRT 70 postoperative mortality 70 LHRH agonists 70 postintervention 70 adenoma recurrence 70 recurrent VTE 69 β blockers 69 F FDG PET 69 flutamide 69 GnRH agonists 69 neoadjuvant 69 corticosteroid therapy 68 adjuvant tamoxifen 68 CR nPR 68 Adjuvant chemotherapy 68 chemoradiotherapy 68 Doxil ® 68 antioxidant supplementation 68 locoregional recurrence 68 postoperative radiotherapy 68 cytoreduction 68 PSADT 68 biochemical recurrence 68 pCR 68 STRIDE PD 68 neoadjuvant chemotherapy 68 GnRH agonist 68 endometrial carcinoma 68 symptomatic VTE 68 virological response 68 recurrent venous thromboembolism 68 advanced adenoma 68 colorectal adenoma 68 cisplatin chemotherapy 67 locoregional 67 Kaplan Meier analysis 67 paclitaxel eluting stents 67 surgical debulking 67 goserelin 67 pelvic lymphadenectomy 67 warfarin therapy 67 androgen suppression therapy 67 hematologic toxicity 67 nonmetastatic prostate cancer 67 estramustine 67 postoperative morbidity 67 relapsed MM 67 nonfatal MI 67 aromatase inhibitor therapy 67 curative resection 67 neurologic progression 67 radiotherapy RT 67 debulking surgery 67 corticosteroid dose 67 pegylated liposomal doxorubicin 67 allogeneic HSCT 67 HBeAg seroconversion 67 chemoradiation therapy 67 conjugated equine estrogen 67 lenalidomide dexamethasone 67 chemoradiation 67 morphometric vertebral fractures 67 MGd 66 antiandrogen 66 mg kg dose 66 perioperative complications 66 clodronate 66 methotrexate therapy 66 endometrial hyperplasia 66 adjuvant therapy 66 NMIBC 66 intravenous bisphosphonates 66 antiangiogenic therapy 66 Radical prostatectomy 66 mycophenolate mofetil 66 lymphadenectomy 66 antithrombotic therapy 66 liver metastasis 66 conventional angiography 66 HER2 expression 66 recurrent glioblastoma multiforme 66 intravitreal injections 66 EGFRIs 66 timepoints 66 thromboembolic 66 EXJADE 66 zoledronate 66 radiochemotherapy 66 H. pylori eradication 66 postoperative AF 66 adjuvant radiation 66 adrenalectomy 66 adriamycin 66 serum estradiol 66 mesalamine granules 66 intensive statin therapy 66 nonvertebral fractures 66 cystectomy 66 dosage regimens 66 perioperative morbidity 66 hemorrhagic complications 66 octreotide LAR 66 CYP#D# inhibitor 66 thromboprophylaxis 66 mitoxantrone 66 CIMZIA ™ 66 metabolic parameters 66 paroxysmal AF 66 pegylated interferon alfa 2b 66 haematologic 66 5-FU/LV 66 KRAS status 66 external beam radiotherapy 66 clinically localized prostate 66 Platinol ® cisplatin 66 lymph node dissection 65 Cardiopulmonary bypass 65 hypoglycemic episodes 65 posttreatment 65 imatinib therapy 65 Thal Dex 65 beam radiotherapy 65 antiandrogens 65 tumor histology 65 ziprasidone 65 CVD mortality 65 doxorubicin docetaxel 65 BRCA2 mutation carriers 65 ibandronate 65 inhaled budesonide 65 thromboembolic events 65 advanced adenomas 65 mTOR inhibitors 65 bilateral oophorectomy 65 methotrexate monotherapy 65 biochemical relapse 65 Neoadjuvant 65 parathyroidectomy 65 perioperatively 65 FOLFOX4 65 leiomyomas 65 KRAS mutations occur 65 FOLPI 65 androgen blockade 65 mycophenolate mofetil MMF 65 rebleeding 65 intravesical therapy 65 nondiabetic patients 65 clinicopathological features 65 radioiodine therapy 65 periprocedural 65 pyridostigmine 65 pharmacokinetic interactions 65 DHEA supplementation 65 ipsilateral stroke 65 skeletal metastases 65 hypofractionated 65 neoadjuvant treatment 65 adrenal suppression 65 prostate cancer CaP 65 PSA nadir 65 ALT elevation 65 tumor resection 65 BEACOPP 65 acromegalic patients 65 LNG IUS 65 adjuvant therapies 65 salmeterol fluticasone 65 mammographic density 65 cerebrovascular events 65 EDSS scores 65 HER2 overexpression 65 subtrochanteric 65 cranial irradiation 65 IFN beta 65 univariate analysis 65 doxorubicin cyclophosphamide 65 tumor regressions 65 metastatic RCC 65 Flu Cy 65 beta blocker therapy 65 paricalcitol 65 lipid lowering therapy 64 histopathologic diagnosis 64 NATRECOR ® 64 randomized multicenter Phase III 64 TEAEs 64 AGILECT R 64 catheter angiography 64 posttransplant 64 dacarbazine chemotherapy 64 PASI scores 64 prednisone prednisolone 64 progression TTP 64 neurocognitive outcomes 64 baseline LDH 64 radiographic progression 64 prospectively stratified 64 tamoxifen therapy 64 virologic failure 64 salpingo oophorectomy 64 histologically confirmed 64 denervation 64 tumor necrosis 64 low dose cytarabine 64 serum homocysteine 64 fibrinolysis 64 desvenlafaxine succinate 64 certolizumab 64 systemic corticosteroid 64 PegIFN RBV 64 antiarrhythmic drugs 64 coadministration 64 thyrotropin levels 64 ATACAND 64 insulin detemir 64 DMARD therapy 64 pamidronate 64 liver resection 64 serum cortisol 64 rFSH 64 radical nephrectomy 64 interferon ribavirin 64 5-fluorouracil/leucovorin 64 selenium supplementation 64 ABVD 64 multivariate Cox 64 oncologic outcomes 64 pneumonectomy 64 sentinel lymph node biopsy 64 % Confidence Interval 64 FOLFIRI alone 64 probiotic supplementation 64 myopathy rhabdomyolysis 64 perioperative mortality 64 Natalizumab 64 Febrile neutropenia 64 DLTs 64 Xelox 64 Postoperative complications 64 sotalol 64 variceal bleeding 64 HMG CoA reductase inhibitors 64 DAPT 64 QTc intervals 64 neutrophil counts 64 divalproex sodium 64 NAbs 64 prospectively defined 64 operable breast cancer 64 intermittent dosing 64 nephrotoxic 64 solifenacin 64 serum concentrations 64 #mg/day [002] 64 albumin excretion rate 64 virologic breakthrough 64 neoadjuvant therapy 64 bezafibrate 64 SLNB 64 recurrent metastatic 64 nonoperative treatment 64 aminotransferases 64 p = #.# [003] 64 CCyR 64 ER CHOP 64 femoral neck fracture 64 mg BID dose 64 adenomatous polyps 64 severe neutropenia 64 concurrent chemoradiation 64 MIRAPEX 64 mitoxantrone chemotherapy 64 tamoxifen Nolvadex ® 64 lumbar spine BMD 64 comparator arm 64 liver biopsies 64 nonmelanoma skin cancers 64 intima media thickness 64 renal tumors 64 unmeasured confounders 64 adjunctive placebo 64 arterial thromboembolic events 64 pulmonary dysfunction 64 Tumor Response 64 % CI #.#-#.# [003] 64 intravenous cyclophosphamide 64 Ceplene/IL-2 64 infusional 63 colorectal liver metastases 63 Tasigna prolongs 63 venous thromboembolic disease 63 complete cytogenetic response 63 serum calcium levels 63 Kaplan Meier 63 tapentadol ER 63 NNRTI resistance 63 adenomatous 63 NATRECOR R 63 serum PSA 63 IOP lowering 63 verteporfin 63 DOXIL 63 cardiac toxicity 63 polyp recurrence 63 chemoprevention trials 63 sleeve lobectomy 63 uric acid lowering 63 echocardiographic parameters 63 plus medroxyprogesterone acetate 63 abacavir lamivudine 63 Subgroup analyzes 63 urate lowering therapy 63 FUSILEV enhances 63 biologic DMARD 63 oral rivaroxaban 63 thromboembolic complications 63 repolarization 63 Thalomid ® 63 argatroban 63 sirolimus eluting stents 63 NNT = 63 alkylating agent 63 tibolone 63 underwent resection 63 carotid IMT 63 HIV HCV coinfected 63 radical cystectomy 63 nodal metastases 63 secondary efficacy endpoint 63 antiangiogenic agents 63 ALND 63 myeloablative 63 gastrointestinal adverse reactions 63 pegylated IFN 63 hepatotoxicity 63 XELOX 63 fluvastatin 63 CR CRu 63 immunosuppressive agents 63 multivariable analysis 63 immunosuppressive regimen 63 VADT 63 antiplatelet therapies 63 epirubicin 63 pharmacologic treatments 63 Pemetrexed 63 HbA 1c levels 63 cilostazol 63 dalteparin 63 moderate renal impairment 63 corrected QT interval 63 multivariate analyzes 63 BYSTOLIC 63 nadroparin 63 multivariate adjustment 63 anthracycline taxane 63 colorectal carcinoma 63 APTIVUS 63 intra abdominal abscess 63 APTIVUS ritonavir 63 QTc prolongation 63 fallopian tube cancers 63 serum urate levels 63 alteplase 63 androgen deprivation therapy 63 demonstrated antitumor activity 63 antitumor effect 63 Subgroup analysis 63 adalimumab 63 symptomatic intracranial hemorrhage 63 #Gy 63 oral prednisolone 63 preintervention 63 tipranavir ritonavir 63 underwent surgical resection 63 estrogen progestin therapy 63 fluorouracil 63 #F FDG PET 63 EUS FNA 63 TURBT 63 pharmacodynamic parameters 63 clomipramine 63 FOLFIRI 63 prucalopride 63 subgroup analyzes 63 axillary node dissection 63 ritonavir boosted 63 canakinumab 63 bisphosphonate therapy 63 histologic subtype 63 #mg dose [002] 63 neurologic complications 63 ALA PDT 63 plasma cortisol 63 FOSRENOL ® 63 hyperalgesia 63 carotid atherosclerosis 63 vaginal hysterectomy 63 hematopoietic cancers 63 oxycodone CR 63 pathologic fractures 63 nadolol 63 weekly subcutaneous injections 63 MAGE A3 ASCI 63 postmenopausal estrogen 63 QTc interval 63 renal cysts 63 oral anticoagulant therapy 63 ancrod 63 oral NSAIDs 63 receptor inhibitor 63 multivariable adjusted 63 adenotonsillectomy 63 anastrazole 63 liver transplant recipients 63 achieved ACR# 63 sulfasalazine 63 olmesartan 63 Akt activation 63 Hydroxyurea 63 oral anticoagulation 63 metastatic gastric 63 severe exacerbations 63 gemcitabine cisplatin 63 conjugated estrogen 63 monoclonal gammopathy 63 pT3 63 Dose escalation 63 Platinol ® 63 antiemetics 63 ALT flares 63 CIMZIA TM 63 interstitial brachytherapy 63 nephrotoxicity 63 achieved CCyR 63 evaluable subjects 63 hepatic resection 62 amenorrhoea 62 danazol 62 patients undergoing CABG 62 node metastases 62 cytoreductive surgery 62 thalidomide Thalomid 62 Retreatment 62 serum creatinine levels 62 cytoreductive nephrectomy 62 genotypic resistance 62 Heavy menstrual bleeding 62 antibiotic prophylaxis 62 PNH patients 62 thrombocytopenic 62 lanthanum carbonate 62 Fulvestrant 62 axillary dissection 62 chemoembolization 62 contralateral breast cancer 62 bicalutamide 62 colorectal adenomas 62 % CI #.#-#.# [007] 62 mTOR inhibition 62 univariate analyzes 62 lymph node metastasis 62 endoscopic resection 62 Stent thrombosis 62 hip BMD 62 intra articular injection 62 median PFS 62 carcinoids 62 TIMP 1 62 hepatic metastases 62 Paraplatin ® 62 graft occlusion 62 HoLEP 62 prostate cancer PCa 62 pretest probability 62 pentoxifylline 62 elevated ALT 62 reinfarction 62 trastuzumab Herceptin ® 62 ziconotide 62 Bezielle 62 cisplatin vinorelbine 62 serum phosphate 62 virologic responses 62 solar keratoses 62 gemcitabine Gemzar 62 nephrectomy 62 K ras mutations 62 tolterodine 62 preoperative radiotherapy 62 alfa 2a 62 IFN alfa 62 prolactin elevation 62 cardiac repolarization 62 loop diuretic 62 immunosuppressive regimens 62 spirometric 62 esophageal carcinoma 62 SUVmax 62 comorbid depression 62 lymph node involvement 62 pharmacokinetic characteristics 62 sipuleucel T 62 histological subtype 62 xenograft models 62 plasma kallikrein inhibitor 62 endometrial thickness 62 pulmonary metastases 62 oral diclofenac 62 adjuvant cisplatin 62 idraparinux 62 teriflunomide 62 ventricular tachyarrhythmia 62 TMP SMX 62 etiologic 62 hip resurfacing arthroplasty 62 BEXXAR Therapeutic Regimen 62 glucocorticoid therapy 62 immunomodulatory therapy 62 docetaxel chemotherapy 62 thrombotic complications 62 PRADAXA #mg 62 atherosclerotic renal artery stenosis 62 intensive lipid lowering 62 amifostine 62 fulvestrant 62 peginterferon 62 Chronic pancreatitis 62 intravenous dosing 62 paroxetine sertraline 62 antihypertensive therapy 62 gadolinium enhanced 62 platelet inhibitor 62 thoracoscopic lobectomy 62 Degarelix 62 menopausal symptom 62 platelet inhibition 62 metachronous 62 total abdominal hysterectomy 62 ertapenem 62 hormone receptor negative 62 orchiectomy 62 dual antiplatelet therapy 62 upper gastrointestinal bleeding 62 recurrent GBM 62 loop diuretics 62 definite stent thrombosis 62 hormone receptor status 62 univariate 62 neurologic sequelae 62 antiarrhythmic drug 62 multivariable Cox 62 R# #mg BID 62 cardiotoxic 62 decitabine 62 tamsulosin 62 ablative therapy 62 peg interferon 62 Pegylated Interferon 62 RRMS patients 62 forodesine 62 virological failure 62 carboplatin paclitaxel 62 renal cell carcinomas 62 mutated K ras 62 atrioventricular block 62 nonpharmacologic 62 hematologic parameters 62 isoproterenol 62 neutropenic patients 62 anthracycline containing 62 thromboembolism 62 hyperprolactinemia 62 pyrazinamide 62 caspofungin 62 malignant neoplasms 62 AST ALT 62 complement inhibitor eculizumab 62 P = .# 62 familial aggregation 62 daunorubicin 62 primary aldosteronism 62 nephron sparing surgery 62 aspirin clopidogrel 62 neurodevelopmental outcome 62 invasive aspergillosis 62 MS relapses 62 unmeasured confounding 62 FIRMAGON 62 dose cohort 62 IV bisphosphonates 62 TNF antagonist 62 Decitabine 62 multivariable adjustment 62 KRAS mutant tumors 62 ribavirin RBV 62 FASLODEX 62 beta carotene supplementation 62 HCV SPRINT 62 oral ibandronate 62 rhTSH 62 antiretroviral naïve 62 unfractionated heparin UFH 62 glycated hemoglobin levels 62 conventional DMARDs 62 renal dysfunction 62 RLAI 62 lung metastasis 62 exemestane 62 Helicobacter pylori eradication 62 Adjuvant therapy 62 cisplatin gemcitabine 62 specific antigen PSA 62 ximelagatran 62 thyroidectomy 62 FOLFIRINOX 62 thiopurine 62 ARB telmisartan 62 trimethoprim sulfamethoxazole 62 5FU 62 TURP 62 elevated transaminases 62 nonmetastatic 62 lymphocyte count 62 coronary stenosis 62 medically inoperable 62 telaprevir dosing 62 contralateral breast 62 GI bleeds 62 virologic response 62 metastatic malignant 62 thromboembolic disease 62 CYP #A# 62 pain palliation 62 GOUT 62 antiplatelet medication 62 microvessel density 62 deferiprone 62 Prostatitis 62 vincristine doxorubicin 62 gout flares 62 otamixaban 62 analgesic medications 62 noncardiovascular mortality 62 fluticasone salmeterol 62 subclinical hypothyroidism 62 transarterial chemoembolization 62 distant metastasis 62 prospective multicenter study 62 Mitoxantrone 62 eplerenone 62 Adefovir 62 antimicrobial prophylaxis 62 logistic regression model 62 revascularizations 62 Exemestane 62 asymptomatic carotid stenosis 62 asthma exacerbation 62 rt PA 61 riociguat 61 poststroke depression 61 lenalidomide Revlimid R 61 rFVIIa 61 CTEPH 61 dysmenorrhoea 61 renal toxicity 61 Capecitabine 61 ARCOXIA 61 symptom exacerbation 61 efalizumab 61 5 Fluorouracil 61 metastatic neuroendocrine tumors 61 undergoing radical prostatectomy 61 chemotherapeutic regimens 61 intraventricular 61 PHPT 61 QALE 61 opioid analgesia 61 atazanavir ritonavir 61 thyroid carcinoma 61 residual confounding 61 mg/m2 dose 61 oral mTOR inhibitor 61 platelet reactivity 61 hemodilution 61 periprocedural MI 61 hypofractionated radiation 61 rHuEPO 61 Hepatotoxicity 61 nonadherence 61 intraoperative complications 61 MGUS 61 labetalol 61 systemic toxicity 61 tolvaptan 61 SGPT 61 Hormone Refractory Prostate Cancer 61 hepatorenal syndrome 61 intravascular hemolysis 61 allogeneic SCT 61 Infusion Reactions Severe 61 systolic hypertension 61 testosterone supplementation 61 aldosterone antagonist 61 EDARBI 61 HBeAg positive patients 61 bolus dose 61 carotid stenosis 61 unresectable tumors 61 Kaplan Meier estimates 61 sitaxsentan 61 parkinsonian symptoms 61 lymph node removal 61 tirofiban 61 Triapine R 61 hematological toxicity 61 doxorubicin HCl 61 cabazitaxel 61 dexamethasone Decadron 61 acute gout flares 61 atrophic gastritis 61 nomograms 61 postoperative complications 61 noncardiac 61 Telintra 61 induce orthostatic hypotension 61 antiepileptic medications 61 venlafaxine XR 61 shorter telomere length 61 INFERGEN 61 adjunctive ABILIFY 61 p = NS 61 Elitek 61 suppressive therapy 61 advanced neoplasia 61 PSA kinetics 61 folinic acid 61 concomitant AEDs 61 SHBG levels 61 CTAP# Capsules 61 Interferon Beta 61 CYT# potent vascular disrupting 61 chlorambucil 61 confidence interval #.#-#.# 61 nab paclitaxel 61 Carotid endarterectomy 61 Hematologic toxicity 61 Tavocept 61 placebo controlled clinical 61 STAT3 signaling 61 placebo controlled trials 61 somatostatin analog 61 neurodevelopmental outcomes 61 Venous thromboembolism 61 seminomas 61 hippocampal atrophy 61 hypophosphatemia 61 Adjunctive 61 unstable angina pectoris 61 postoperative atrial fibrillation 61 micafungin 61 vidofludimus 61 ARIMIDEX 61 INVEGA ® 61 CDI recurrence 61 LV dysfunction 61 PCWP 61 oral antidiabetic medication 61 plasma pharmacokinetics 61 bone metastasis 61 letrozole Femara 61 TT genotype 61 dose Iluvien 61 thalidomide dexamethasone 61 activated partial thromboplastin 61 idarubicin 61 paclitaxel cisplatin 61 antithymocyte globulin 61 Menopausal hormone therapy 61 ovarian carcinoma 61 Adenomas 61 leucopenia 61 ritonavir boosted lopinavir 61 distant metastases 61 erlotinib Tarceva 61 PREZISTA r 61 monoinfected patients 61 Peg IFN 61 salmeterol HFA MDI 61 cutaneous squamous cell carcinoma 61 HER2 positivity 61 plasminogen activators 61 postprocedure 61 patients evaluable 61 proximal DVT 61 intermittent hypoxia 61 corticosteroid dexamethasone 61 lactate dehydrogenase 61 percutaneous vertebroplasty 61 overlapping toxicities 61 extrapyramidal symptoms 61 logistic regression analyzes 61 hormone therapy estrogen 61 selenium intake 61 cytotoxic therapies 61 proliferative diabetic retinopathy 61 TNF blocker therapy 61 prostate carcinoma 61 confidence intervals CIs 61 CYP#D# genotype 61 PROSTVAC VF 61 eculizumab therapy 61 rimonabant #mg 61 epidural steroid injections 61 metastatic GIST 61 viral kinetics 61 adjuvant chemotherapy 61 adjuvant systemic 61 bone scintigraphy 61 IM progesterone 61 CI #.#-#.# [001] 61 PCa 61 urothelial cancer 61 NSABP B 61 intact parathyroid hormone 61 ACZ# 61 p = .# [002] 61 nutlin 3a 61 chorioamnionitis 61 NPH insulin 61 allogeneic stem cell 61 LUTS 61 tumorigenicity 61 external genital lesions 61 Polyp Prevention Trial 61 transurethral 61 hydroxychloroquine 61 PREMPRO 61 GH deficiency 61 placebo dexamethasone 61 dosing cohort 61 aminotransferase levels 61 budesonide foam 61 lipid lowering therapies 61 recurrent myocardial infarction 61 neutropenia dehydration dyspnea 61 Erythropoietic therapies may 61 FDG PET imaging 61 mitoxantrone plus 61 TP# mutations 61 pharmacodynamic effects 61 myocardial reperfusion 61 axillary lymph node dissection 61 GI toxicity 61 hepatocellular carcinomas 61 antiplatelet drugs 61 calcaneal fractures 61 BCIRG 61 Hypotension 61 transurethral resection 61 HCV RESPOND 2 61 myelosuppressive 61 mutated KRAS 61 endosonography 61 antiepileptics 61 papillary renal cell carcinoma 61 left ventricular dysfunction 61 malignant neoplasm 61 VT VF 61 adjuvant hormonal therapy 61 variceal hemorrhage 61 Adjuvant Therapy 61 BENICAR HCT 61 β blocker 61 HPV-#/# 61 serum aminotransferase levels 61 alanine aminotransferase ALT 61 cerebral vasospasm 61 trials RCTs 61 selective modulator 61 interferon IFN 61 dose dexamethasone 61 hepatectomy 61 angiographic outcomes 61 renoprotective 61 axillary node 61 benign prostatic hyperplasia enlarged 61 cardiotoxicity 61 TLUS 61 baseline FEV 61 tipranavir r 61 hypomagnesemia 61 ACTEMRA TM 61 μmol L 61 tacrolimus ointment 61 pharmacologic intervention 61 prolactin levels 61 metastatic lung cancer 61 sorafenib Nexavar 61 chronic GVHD 61 anthracycline therapy 61 FROVA 61 tracer uptake 61 intratympanic 61 CC genotype 61 oral clodronate 61 gemifloxacin 61 octreotide 61 plus dexamethasone 61 EDEMA3 trial 61 hyperoxaluria 61 pulmonary artery banding 61 Anthracycline 61 serum HCV RNA 61 perfusion abnormalities 61 concomitant medications 61 airway responsiveness 61 refractory ischemia 61 Nilotinib 61 GnRH antagonist 61 PSMA ADC 61 Randomized trials 61 overt nephropathy 61 oral deforolimus 61 CsA 61 venlafaxine Effexor 61 Temsirolimus 61 mRCC 61 antiplatelet therapy 61 corifollitropin alfa 61 adenoidectomy 61 elevated LDH 61 drug eluting stent implantation 61 coronary arteriography 61 vitamin B# folic acid 61 Surgical excision 61 scintigraphic 61 Index CDAI 61 histologically proven 61 Teriflunomide 61 IFN α 61 AZOR 61 cytologic 61 ribavirin therapy 61 atherogenic dyslipidemia 61 glucose abnormalities 61 dose atorvastatin 61 EFFEXOR XR 61 tryptophan depletion 61 heavily pretreated patients 61 subchronic 61 colorectal adenocarcinoma 61 epithelial tumors 61 resectable 61 micrometastasis 61 Zevalin consolidation 61 HSCT 61 galiximab 61 amisulpride 61 antidepressant therapy 61 standard chemotherapy regimen 61 ovarian suppression 60 deep venous thromboses 60 angiographically 60 leukocyte counts 60 liver histology 60 osteoporotic vertebral compression fractures 60 HBeAg negative 60 intracranial stenosis 60 AML MDS 60 invasive ductal 60 mL/min/#.# m 2 60 agomelatine 60 pulmonary exacerbations 60 pomalidomide 60 nodal dissection 60 serum urate 60 CYPHER Stent 60 azacitidine 60 Patients Receiving 60 antibody titer 60 AVODART 60 primidone 60 coxib 60 timepoint 60 mucinous 60 nocturnal hypoglycaemia 60 intravesical 60 neutropaenia 60 recurrent DVT 60 extramedullary 60 CIN2 +